NasdaqGS:HALOBiotechs
Halozyme Acquisitions And ENHANZE Growth Shape Long Term Valuation Story
Halozyme Therapeutics (NasdaqGS:HALO) has agreed to acquire Hypercon and several biotech startups, expanding its drug delivery and platform capabilities.
The Hypercon deal extends Halozyme’s intellectual property coverage into the 2040s, supporting long term use of its core technologies.
The company recently reported new ENHANZE-enabled collaborations and fresh global regulatory approvals for subcutaneous formulations using its platform.
Halozyme Therapeutics, trading at $69.4, has recorded...